Navigation Links
Shire Delivers Strong First Quarter Performance and Reiterates its Expectation of Good Full Year Earnings Growth
Date:4/26/2012

: Millions Millions Basic[(1)] 553.5 549.5 Effect of dilutive shares: Share based awards to employees[(2)] 8.6 10.9 Convertible bonds 2.75% due 2014[(3)] 33.5 33.2 Diluted 595.6 593.6

[(1)]. Excludes shares purchased by the Employee Benefit Trust and presented by Shire as treasury stock.

[(2)]. Calculated using the treasury stock method.

[(3)]. Calculated using the "if converted" method.


The share equivalents not included in the calculation of the diluted weighted average number of shares are shown below:

3 months to March 31, 2012 2011 No. of shares No. of shares Millions[(1)] Millions[(1)] Share based awards to employees 6.1 7.5

[(1)]. Certain stock options have been excluded from the calculation of diluted EPS because (a) their exercise prices exceeded Shire's average share price during the calculation period or (b) the required performance conditions were not satisfied as at the balance sheet date.


Unaudited US GAAP results for the three months to March 31, 2012

Selected Notes to the Financial Statements

(2)  Analysis of revenues

3 months to March 31, 2012 2011 2012 2012 % % of total $M $M change Revenue Net product sales: Specialty Pharmaceuticals ("SP") ADHD VYVANSE 260.0 202.3 29% 22% ADDERALL XR 111.4 111.2 0% 9% INTUNIV 68.5 41.9 63% 6% EQUASYM 7.2 4.6 57% <1% 447.1 360.0 24% 37% Gastro Intestinal ("GI") LIALDA/MEZAVANT 90.0 87.1 3% 8% PENTASA 65.8 64.5 2% 6% RESOLOR 2.4 0.9 167% <1% 158.2 152.5 4% 14% General products FOSRENOL 45.5 41.2 10% 4% XAGRID 23.2 22.7 2% 2% 68.7 63.9 8% 6% Other product sales 32.7 39.7 -18% 3% Total SP product sales 706.7 616.1 15% 60% Human Genetic Therapies ("HGT") REPLAGAL 134.4 105.4 28% 11% ELAPRASE 125.6 103.5 21% 11% VPRIV 71.7 59.0 22% 6% FIRAZYR 19.7 5.3 272% 2% Total HGT product sales 351.4 273.2 29% 30% Regenerative Medicine ("RM") DERMAGRAFT 48.8 - n/a 4% Total RM product sales 48.8 - n/a 4% Tota
'/>"/>

SOURCE Shire plc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25

Related medicine technology :

1. Shire Strives to Increase Adherence Among Chronic Kidney Disease Stage 5 Patients
2. Shire Enhances its Orphan Drug Pipeline With the Acquisition of a New Clinical Candidate for Metachromatic Leukodystrophy
3. Shire to Present Additional Scientific Data on ADHD Treatment Portfolio at American Psychiatric Association Annual Meeting
4. Shires Investigational Nonstimulant ADHD Treatment INTUNIV(TM) (Guanfacine Extended Release) Demonstrated Significant Efficacy in Reducing ADHD Symptoms at All Measured Time Points Up to 24 Hours Postdose
5. Shire Announces Approval of ELAPRASE(R) (idursulfase) in Brazil
6. Shire to add New Orphan Drug to its HGT Portfolio - EU Launch Imminent
7. Shire Withdraws European Application for DAYTRANA(TM) (Methylphenidate Transdermal System)
8. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
9. Shire Presented Results of a New Database Analysis on Lialda(R) (Mesalamine) and Other 5-ASAs for Ulcerative Colitis at Digestive Disease Week
10. Shire has Filed a Treatment Protocol for Velaglucerase Alfa for Gaucher Disease
11. Shire Receives Fast Track Designation for velaglucerase alfa for Gaucher Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... WORTH, Texas , Jan. 15, 2014  Humberto C. ... Dermatology Achievement Award" from the Journal of Drugs ... Aesthetic & Clinical Conference (ODAC). The event is January 17-20, ... Florida . The ODAC ...
(Date:1/15/2014)... is very pleased to announce the appointment of Mr. ... Mark was promoted from his current role of Chief Operating ... in Massachusetts , Mississippi ... 2012 with 20+ years of broad-based operations, sales, engineering and ...
(Date:1/15/2014)... , Jan. 15, 2014  According to Millennium ... technology market intelligence, the United States ... (TEO) device markets will expand moderately through 2022, ... segments. In particular, increasing interest in drug-eluting beads ...
Breaking Medicine Technology:Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Tegra Medical Appoints New Chief Executive Officer 2Tegra Medical Appoints New Chief Executive Officer 3US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3
... NEW YORK, March 14, 2011 Reportlinker.com announces ... in its catalogue: Global Cardiac ... http://www.reportlinker.com/p0240523/Global-Cardiac-Monitoring-Systems-Market-2009-2013.html With advancements in technology, ... capabilities have been introduced in the Cardiac Monitoring ...
... 2011 Reportlinker.com announces that a new market ... Hepatitis A Preventive Vaccines - Pipeline ... http://www.reportlinker.com/p0453473/Hepatitis-A-Preventive-Vaccines---Pipeline-Assessment-and-Market-Forecasts-to-2017.html Hepatitis A ... to 2017 SummaryGlobalData, the industry ...
Cached Medicine Technology:Reportlinker Adds Global Cardiac Monitoring Systems Market -2013 2Reportlinker Adds Global Cardiac Monitoring Systems Market -2013 3Reportlinker Adds Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2017 2Reportlinker Adds Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2017 3
(Date:4/23/2014)... Va., April 23, 2014 The American Society for ... "The Role of Postoperative Radiation Therapy for Endometrial ... use of adjuvant radiation therapy in the treatment ... published in the May-June 2014 issue of ... practice journal of ASTRO. The full-length guideline is ...
(Date:4/23/2014)... A novel compound that targets an important brain ... cocaine addiction behaviors, including relapse behavior, a University at ... strong evidence that this may be a novel lead ... medications exist., The UB research was published as an ... , In the study, the compound, RO5263397, severely blunted ...
(Date:4/23/2014)... science, "simple and accessible detection methods that can ... resolution of a single cell inside that population ... engineer Chang Lu. , In the Royal Society ... has announced that he and his coworkers have ... location of a protein ( Chem. Sci. , ...
(Date:4/23/2014)... the United States, it may come as a surprise that ... food due to lack of money or other financial resources. ... University of Illinois using data from the National Health and ... dealing with hunger are also facing negative health and nutrition ... age 60 faced the threat of hungerthat translates to 4.8 ...
(Date:4/23/2014)... Leisure Time Physical Activity on Mobility Limitation in Old ... the risk of mobility limitation in old age, whereas ... in a study which followed up 5,200 public sector ... the Gerontology Research Center in Finland and the Finnish ... often repetitive, wears the body and lasts for several ...
Breaking Medicine News(10 mins):Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:More Americans in their golden years are going hungry 2Health News:Midlife occupational and leisure-time physical activity limits mobility in old age 2
... of Science supports the protocol to reverse type 1 diabetes ... cells// from the spleen can add to the renewal of ... Hospital (MGH) showed the benefits of a procedure to turnaround ... from other institutions published in the March 24, 2006 issue ...
... reportedly swallowed tiny magnets that fell off toys had ... Product Safety Commission has// ordered a major recall of ... Mattel.,Mattel is an El Segundo-based toy manufacturer. ... complaints reporting that small magnets fell out of the ...
... stem cells increase insulin production in mice with type 2 ... diabetes, say Tulane University gene// therapy researchers. The article is ... Proceedings of the National Academy of Sciences. ... They have the potential to be used therapeutically because of ...
... Keio Medical Science Award from Keio University in Tokyo. ... at Yale, received the award in a ceremony and commemorative ... ,The award, made to researchers in recognition of their ... is the only prize of its kind awarded by a ...
... 2006 there are 57 million underweight children in India.// ... under the National Rural Health Mission (NRHM) to overcome ... Implementing the Integrated Management of Childhood Illnesses (IMNC) which ... childhood illnesses and malnutrition. ,2. Implementation ...
... Department for Health (DoH), UK has launched a new scheme ... to provide healthy nutrition to toddlers between 1// and 4 ... below 18. ,The Healthy Start scheme offers vouchers, ... supplements, milk or infant formula. Households with children under one ...
Cached Medicine News:Health News:New data from NIH lab confirms protocol to reverse type 1 diabetes in mice 2Health News:Yale Scientist Received Medical Science Prize From Keio University 2
Auto Refkeratomoeter...
... The InfusO.R. Pump is a ... aid in the administration of ... anesthetic procedures. It provides for ... muscle relaxants, and vasoactive drugs ...
Developed to meet the infusion needs in NICU, Anesthesia and Critical Care, the AUTO SYRINGE AS50 Infusion Pump delivers precise, controlled infusions....
Pain management can be complicated. But that doesn't mean your PCA infusion system should be. The new SYNDEO PCA Syringe Pump streamlines pain therapy with a powerful combination of intelligent desig...
Medicine Products: